Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultrasound monitoring of apremilast and secukinumab treatment in psoriatic arthritis
NL-OMON46720Active, not recruiting
- Sponsor
- Reade
- Start
- May 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of apremilast and secukinumab in psoriatic arthritis (PsA) (3 cohorts), sponsored by Reade. Started May 2018; status: active, not recruiting.
02
Drugs
apremilastsecukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON46720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46720.